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Abstract
It has been increasingly recognized that antimicrobial stewardship (AMS) has to be a key component of any efforts that aim to mitigate the
current global antimicrobial resistance (AMR) crisis. It has also become evident that AMR is a problem that cannot be tackled by single
institutions or physicians, but needs concerted actions at regional, national and supra-national levels. However, it is easy to become
discouraged, given the problems that are often encountered when implementing AMS. The aim of this review is to highlight some of the
success stories of AMS strategies, and to describe the actions that have been taken, the outcomes that have been obtained, and the
obstacles that have been met. Although the best approach to effective AMS remains elusive and may vary signiﬁcantly among settings, these
diverse examples from a range of healthcare contexts demonstrate that effective AMS is possible. Such examples will inform others and
encourage them to formally evaluate and share their results with the global stewardship community.
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Antimicrobial resistance (AMR) is a problem requiring global
solutions; antimicrobial stewardship (AMS) is a key component
in addressing this issue [1]. However, many hospitals across
the globe still lack AMS programmes, primarily because of a
lack of funding (Howard, 2013 23rd ECCMID, Abstract O475).
The results from published surveys suggesting that approxi-
mately half of all hospitals have AMS programmes very likely
represent an overestimation of the true prevalence of AMS
activities, owing to signiﬁcant non-response bias and the use of
rather broad deﬁnitions of what constitutes an AMS
programme. This low level of activity is a concern, given that
there is now good evidence that AMS programmes in hospitals
can reduce overall antibiotic use and have a positive impact on
the incidence of Clostridium difﬁcile infection (CDI) and possibly
also on AMR and clinical outcomes [2,3].
All too often, discussions about AMS are restricted to the
inpatient setting, where there is high antibiotic use, a
vulnerable patient population, and ‘ideal’ conditions for the
transmission of multidrug-resistant organisms (MDROs). Most
antibiotic use, however, occurs in the community, and often
involves antibiotics for self-limiting viral infections in otherwise
healthy people [4]. However, in the community setting, there
have been many large-scale antibiotic awareness campaigns
conducted at regional and national levels, and some have been
‘successful’ in reducing outpatient antibiotic use [5,6].
This narrative review aims to illustrate some of the ‘success
stories’ of AMS—deﬁned as any intervention aimed at
improving the use of antimicrobials—implemented on a larger
scale. Obviously, this leads to the question of how ‘success’
should be deﬁned in the context of AMS: a reduction in overall
antibiotic use and by what measure, a reduction in the use of
speciﬁc antibiotic classes, a reduction in key outcomes such as
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the incidence of infections with MDROs or CDI, or even
changes in mortality. The metrics for measuring these
outcomes remain challenging to deﬁne, obtain, and interpret,
but are crucial if we are to convince healthcare managers and
policy-makers to invest increasingly scarce resource in AMS
[7]. Ultimately, ‘success’ is, however, in the eye of the
beholder, and in this review we did not tie our perception of
‘success’ to speciﬁc outcomes, as these are often not available,
and the implementation of AMS activities alone in a large
setting can already sometimes represent a ‘success’ story,
given the many obstacles.
It is important to keep in mind that this review is not aimed
to be a comprehensive, systematic description of worldwide
AMS activities. It is rather aimed at providing a broad
description of some encouraging AMS stories from a conve-




Fluoroquinolones are known as an antibiotic class with a
particularly detrimental impact on the selection and spread of
AMR [8,9]. In Australia, this was recognized earlier than
elsewhere, and the use of this antibiotic class has long been
restricted by guidelines favouring alternative options, and the
limitation of prescription subsidies for this antibiotic class by
the Pharmaceutical Beneﬁts Scheme to very speciﬁc indications
recognized by the guidelines [10]. As a consequence, Australia
is one of the lowest overall users of ﬂuoroquinolones among
high-income countries (less than 0.6 deﬁned daily doses/1000
inhabitants per day, whereas most European countries are
well above one deﬁned daily dose/1000 inhabitants per day),
and, despite relatively high overall antibiotic use in the
community, rates of resistance to ﬂuoroquinolones are low
as compared with many European countries (in 2010, 5.2% of
Escherichia coli isolates from community-acquired infections
were ﬂuoroquinolone-resistant in Australia, whereas for
most European countries this proportion is well above 15%)
(EARS-Net: http://www.ecdc.europa.eu/en/healthtopics/anti
microbial_resistance/database/Pages/database.aspx (accessed
16 October 2014)) [10–12].
Australia has also been active in inpatient AMS. The
Australian Commission on Safety and Quality in Health Care
—a government agency—has made surveillance of AMR and
antibiotic usage a priority, and since 2013 AMS has become a
criterion for accreditation of health services. In particular,
hospitals are required to have an AMS programme in place,
provide treatment guidelines, and monitor antibiotic use. The
recent introduction of measurable clinical standards for
stewardship in Australian hospitals will enhance the pivotal
place of stewardship in everyday clinical practice. The impact
of this is awaited with interest.
Chile
Dispensing of antibiotics without a medical prescription is a
problem in many low-income and middle-income countries,
where regulations are either non-existent or insufﬁciently
enforced [13,14]. In 1999, Chile implemented a policy
enforcing a ban of over-the-counter use of antibiotics without
prescription [15]. The policy, also accompanied by a public
campaign, was associated with a rapid 30% decrease in overall
antibiotic use during the ﬁrst years after its implementation
[16,17]. Unfortunately, antibiotic use increased again between
2003 and 2008, but remains below that in the pre-intervention
period [15]. Although the reasons for the increase are unclear
(the lack of monitoring of compliance with the measures and
the absence of additional interventions are mentioned in the
literature), it illustrates that the long-term sustainability and
associated cost/beneﬁt ratio of AMS interventions need to be
considered [15].
China
Like other countries, China has seen a rapid increase in
MDROs over the last decade, and overprescribing of antibi-
otics is common in all settings, as is self-medication with
antibiotics in the general population [18–21]. The Chinese
Ministry of Health has recognized the dire situation, and
launched a national campaign in 2011 to promote AMS in
healthcare settings by establishing mandatory administrative
strategies for the rational use of antimicrobials with ﬁxed
targets and audits [22]. Long-term data on the impact of these
actions are lacking, but preliminary analyses suggest that there
may have been a reduction in antibiotic use in the outpatient
and inpatient settings between 2011 and 2012 (the proportion
of patients prescribed an antimicrobial decreased from 68% to
58% for the inpatient setting, and from 25% to 15% for the
outpatient setting) [22,23]. Although it is encouraging that the
world’s most populous country is taking the problem of
antibiotic misuse seriously, it is unclear whether predeﬁned
government targets for antibiotic use really constitute the best
approach to ensure appropriate use for all patients.
France
France has one of the highest levels of outpatient antibiotic use
in Europe [24]. Over the last decade, France implemented
three national action plans (2001–2005, 2007–2010, and 2011–
2016) to preserve the effectiveness of antibiotics. As part of
the action plans, an intensive yearly public campaign called
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Country Interventions Success and failures Selected 
references
Australia Restriction of fluoroquinolone use Low fluoroquinolone use and low proportion of 
fluoroquinolone-resistant Escherichia coli 
Very high overall antibiotic use
[10]
Chile Enforcement of a sales restriction 
for antibiotics (‘prescription only’) 
in 1999 in combination with a public 
campaign
Decrease in antibiotic consumption from
DID in 1999 to 8.5 DID in 2000
Overall antibiotic use has been increasing again since 
[15—17]
then
China Implementation of a 
comprehensive campaign to 
promote rational antibiotic use in 
2011 :
• audit and inspection 
• requirement for hospitals 
to have an antibiotic 
administrative group
• formulary restrictions 
• clear targets for antibiotic 
use (less of 60%/20% of 
patients prescribed an 
tibiotic in the inpatient/
outpatient setting; less 
than 40 DDD/100 patient-
days in the inpatient 
setting)
Proportion of patients prescribed an antimicrobial 
decreased from 68% to 58% for the inpatient setting and from 
25% to 15% for the outpatient setting between 2011 and 
2012
Fixed targets for antibiotic use seem problematic 
(impact on patient outcomes ?)
[19,22,23]
France Yearly national antibiotic campaign 
since 2001
Overall outpatient antibiotic prescriptions per 100 
inhabitants decreased by 26.5% over the first few 
campaign winters
Overall antibiotic use remains high as compared with other 
European countries and has been increasing in recent 
years
[25,26,28]
Scotland National antibiotic stewardship 
programme since 2008




amoxiclav and clindamycin 
(target: CDI)
Net decrease in the incidence of CDI between 2008 
and 2013
Increase in nephrotoxicity resulting from aminoglycoside use. 
Unclear how much of the decrease in CDI is attributable to 
antibiotic stewardship or attributable to concomitant 
interventions
[3,29,30]
South Africa Implementation of an AMS 
programme in a private network of 
hospitals since 2010
Net decrease in overall antibiotic use (Fig. 3)
Overall antibiotic use remains high. programme limited to 
the private setting
South Korea National policy change in 2000 Net decrease in antibiotic prescribing for patients with [35]
• Separation of prescribing 
and dispensing of 
antibiotics
presumed viral illness between 2000 and 2001 (from 
80.8% to 72.8%)
Long-term impact unclear. Overall antibiotic use for 
respiratory tract infections remains high.
Sweden National programme to contain 
antibiotic resistance (Strama) 
involving all stakeholders
• Elaboration of guidelines
• Identification and filling of 
knowledge gaps
Low overall antibiotic use and low resistance levels
Increase in hospital antibiotic use over the last 
decade
[39,42,44]
Taiwan Implementation of a policy 
restricting reimbursement for 
antimicrobials in ambulatory 
patients with upper respiratory 
infections to situations where 
evidence of bacterial involvement 
is provided in 2001
Net decrease in antimicrobial use for respiratory 
infections (from DID in 
1999 to 10.0 DID in 2001)
Long-term impact unclear
[36,37]
USA Public campaign since 1995 Decrease in outpatient antibiotic use
Overall antibiotic use remains high.
[50]
Vietnam Vietnam Resistance (VINARES) 
project : 
• promotion of prudent 
antibiotic use
• strengthening of laboratory 
and surveillance activities
Too early to judge [54]
FIG. 1. Global success stories of antimicrobial stewardship (AMS) mentioned in this review. CDI, Clostridium difﬁcile infection; DDD, deﬁned daily
doses; DID, deﬁned daily doses/1000 inhabitants per day; Strama, Swedish Strategic Programme Against Antibiotic Resistance.
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‘Antibiotics are not automatic’ was conducted from 2002. It
was associated with a > 25% reduction in antibiotic prescrip-
tions per 100 inhabitants over the ﬁrst few years of the
campaign [25]. The campaign was remarkable not only for its
scope, but also for the inclusion of interventions targeting
physicians through detailing and massive promotion of a rapid
streptococcal antigen test in combination with a clinical score
for sore throat [5]. Unfortunately, the impact of the campaigns
has levelled off; overall outpatient use remains high and has
even been increasing in recent years, illustrating again the
challenges in achieving sustainable success with AMS interven-
tions [26–28]. The reasons for this remain unclear and need
further elucidation. Since 2011, a new information campaign
with slightly different messages has been conducted. It remains
to be seen whether it will be successful.
Scotland
The Scottish Antimicrobial Prescribing Group was established
by the Scottish government in 2008 to lead a national AMS
programme across all healthcare communities. Through the
use of a range of interventions, the primary goals of the
national programme were to reduce or stabilize resistance
rates, improve clinical outcomes of patients with infection or
those undergoing a range of common surgical procedures, and
improve safety by reducing harm from antibiotic-related
toxicity. However, in light of the epidemic of CDI at that
time, the immediate focus was on reducing CDI rates, a key
ecological consequence of antibiotic misuse. Reduction in the
use of classes of antibiotics that are more commonly
associated with CDI, the ‘4C’ (cephalosporins, ciproﬂoxacin
and other ﬂuoroquinolones, co-amoxiclav, and clindamycin)
approach, was a key intervention, linked to promotion of
older classes of antibiotics (co-trimoxazole, amoxycillin, tet-
racyclines, and aminoglycosides) [29]. After implementation
and measurement, performance feedback with regard to the
process indicators was provided to antimicrobial and
clinical teams [3]. Uniquely, the programme also aimed from
the beginning to assess prospectively any unintended con-
sequences of the AMS interventions, such as changes in
all-cause 30-day mortality. Preliminary data from one region do
not suggest any change in this outcome resulting from
interventions (Patton A, personal communication). A further
measure concerned the negative impact of a change in surgical
prophylaxis on renal function in a subset of patients with hip
arthroplasty (from cefuroxime to ﬂucloxacillin and gentami-
cin). Analysis of data from a retrospective cohort of patients
undergoing surgery with antibiotic prophylaxis in a single
Scottish region conﬁrmed an increase in the incidence of acute
kidney injury associated with the policy in orthopaedic patients
(Fig. 2), and guidelines were adapted accordingly [30]. The
Scottish experience illustrates how important it is to measure
unintended consequences of AMS. Furthermore, the real-time
assessment of the effectiveness of AMS and infection control
interventions made possible through electronic data linkage of
existing or routine databases will hopefully soon provide a
wealth of new evidence in the domain of AMS (www.
isdscotland.org/iip).
South Africa
Few data are available on the epidemiology of AMR, the level
of antibiotic use and the implementation AMS activities on the
African continent. In an international survey of hospital AMS
activities, Africa was the continent with the fewest AMS
programmes in place (six of 42 (14%) hospitals as compared
with 58% overall) (Howard, 2013 23rd ECCMID,
Abstract O475). Nevertheless, there is some encouraging
news from South Africa, albeit mainly from the private sector.
The largest private hospital network in South Africa (Netcare
(a)
(b)
FIG. 2. Gentamicin-induced acute kidney
injury following the change in surgical
prophylaxis antibiotics as part of a
national stewardship programme in
Scotland. (a) Increase in the percentage
of acute kidney injury (adjusted) stages 1,
2 and 3 for each month (excluding neck of
femur fractures) following the policy
change. (b) No increase in the
percentage of acute kidney injury
stage 1, 2 and 3 for each month in
patients with a neck of femur fracture.
From [30] with permission.
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Ltd) has responded to the threat posed by carbapenem-
ase-producing enterobacteria by establishing an AMS pro-
gramme, which has been progressively implemented in its 55
hospitals since 2010 [31]. The program adopted the Institute
for Healthcare Improvement breakthrough series collaborative
approach, involving multidisciplinary teams containing pharma-
cists, infection control practitioners, microbiologists, and
other clinicians [32]. Data collection for surveillance was
automated, speciﬁc outcome measures and deliverables were
established (with ranking of the hospitals according to their
implementation of AMS), workshops and teleconferences
were organized, and guidelines were developed. Preliminary
data suggest that the programme was associated with a 12.1%
reduction in deﬁned daily doses per 100 patient-days by the
ﬁrst trimester of 2014 (Fig. 3) (D. van den Bergh, personal
communication). Although the overall level of antibiotic use
remains high, at approximately 82 deﬁned daily doses per 100
patient-days, these results are certainly encouraging, and
provide an example to follow for other hospital networks in
Africa and elsewhere.
South Korea and Taiwan
Certain regulatory frameworks can create economic incen-
tives that counteract the prudent use of medications in general
and of antibiotics in particular [33]. The failure to separate
prescribing and dispensing of medications in some regions of
Switzerland has, for example, been shown to be associated
with higher levels of antibiotic use [34]. In South Korea, this
problem was recognized, and a pharmaceutical policy reform
was implemented in 2000, prohibiting physicians from dispens-
ing drugs [35]. This policy change was associated with both a
reduction in antibiotic use and an increase in the quality of
antibiotic prescribing [35].
Taiwan implemented a similar policy in the 1990s [36]. In
addition, in 2001, the national health insurance in Taiwan
implemented a policy stopping reimbursement for acute upper
respiratory tract infections unless proof of bacterial aetiology
was provided. In the ﬁrst year, this policy was associated with a
> 50% reduction in antibiotic use for upper respiratory tract
infections [37,38].
Sweden
Sweden was one of the ﬁrst countries to adopt a universal,
national strategy for AMS in all settings (including the
veterinary sector). The Swedish Strategic Programme Against
Antibiotic Resistance (Strama), which started as an informal
network in 1995, was institutionalized as an independent
governmental body in 2006 [39]. Local Strama groups coop-
erate with hospital stewardship programmes to develop
guidelines [40]. At the national level, one of the key
accomplishments of Strama is the initiation of trials addressing
key knowledge gaps in AMS, such as the recently published
randomized controlled trial conﬁrming the non-inferiority of
7-day vs. 14-day treatment in women with acute pyelonephritis
[41]. Although hospital antibiotic use in Sweden appears to
have increased in recent years, it still remains comparatively
low, and the level of antibiotic use in the outpatient setting is
among the lowest in Europe [24,42]. In that context, it is
remarkable that Strama also dedicated efforts to assess
potential negative consequences of reduced antibiotic use in
the community, an aspect that is often neglected [43,44].
Demonstrating that a decrease in antibiotic use (from an
already very low level) is not associated with an increase in
complications such as mastoiditis and quinsy constitutes
extremely valuable information for other countries [43,44].
USA
The USA was among the ﬁrst high-income countries to
implement an antibiotic campaign to educate the public, in
1995, with the CDC ‘Get Smart’ programme. As the USA has
somewhat lagged behind Europe with regard to the surveil-
lance of antimicrobial use, it is, however, difﬁcult to assess the
impact of the campaign [5,45]. Fortunately, more data have
become available recently [46–48]. It seems that outpatient
antibiotic prescriptions have been somewhat decreasing since
the turn of the century, at least for some subgroups, such as
children and adolescents [4]. Unnecessary use of antibiotics for
acute respiratory tract infections and the use of antibiotics
with an unnecessarily broad spectrum, such as macrolides and
ﬂuoroquinolones, remain common [4]. It is promising that
there are plans for the CDC’s Get Smart campaign and the
FIG. 3. Impact on antibiotic consumption following implementation
of an an antimicrobial stewardship programme across a group of 54
private hospitals in South Africa (D. van den Bergh, personal
communication; with permission of author). DID, deﬁned daily
doses/1000 inhabitants per day.
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European Centres for Disease Prevention and Control Euro-
pean Antibiotic Awareness Day to further coordinate efforts
to educate the public about appropriate antibiotic use
(Transatlantic Taskforce on Antimicrobial Resistance—Pro-
gress report 2014; http://www.cdc.gov/drugresistance/pdf/
TATFAR-Progress_report_2014.pdf (accessed 16 October
2014)) [49]. Recently, the CDC has also turned its attention
to the inpatient setting, with the ‘Get Smart for Healthcare’
programme. A strategy for monitoring inpatient antimicrobial
use among hospitals is currently being implemented [50]. The
Veterans Health Administration, the largest integrated health-
care system in the USA, has recently also become very active
in the context of AMS, with mandatory implementation of
AMS at all Veterans Health Administration medical facilities by
mid-2014. The availability of a common electronic health
record with detailed patient-level data will make it interesting
to follow the impact of this policy.
Vietnam
In 2013, a report analysed the situation with regard to
antibiotic use and resistance in Vietnam [51]. The report
draws a rather dire picture, with frequent antibiotic misuse in
all settings, and proposes some policy priorities to address the
problem, among them being the development of AMS
programmes [52,53]. In order to assist local healthcare
professionals with the task of strengthening AMS and infection
control, the Vietnam Resistance (VINARES) project was
initiated [54]. The project has a comprehensive approach,
and aims to meet the policy priorities proposed by the WHO
in 2011 as a ‘policy package’ to combat AMR that includes both
the promotion of prudent antibiotic use and also the
strengthening of laboratory and surveillance activities [55]. A
recently published paper described the implementation of the
project and the challenges that it has met so far [54]. Although
it is too early to judge whether VINARES really is a ‘success
story’, it is certainly promising, and may be an example to
follow for other low-income and middle-income countries.
Discussion
With the emergence and spread of multiresistant Gram-neg-
ative ‘superbugs’, the need for effective AMS has been
recognized in most settings as a key strategy to counter this
threat. In this review, we have presented some examples
illustrating that AMS activities can be successfully implemented
in a variety of geographical and socio-economic settings. There
certainly are more success stories in other countries (e.g.
Belgium, Slovenia, and Thailand), not to mention in individual
hospitals and practices, that are not included in this review
[56–58]. In general, antibiotic stewards around the world
should be encouraged to share more often their real-life
experiences in medical journals.
A recent booklet on hospital stewardship sponsored by a
diagnostic company provides further pragmatic good-practice
examples of stewardship in action (http://bsac.org.uk/wp-con-
tent/uploads/2013/07/Stewardship-Booklet-Practical-Guide-to-
Antimicrobial-Stewardship-in-Hospitals.pdf (accessed 16 Octo-
ber 2014)).
It is evident that AMS is just one element in the quest to
combat AMR and that a comprehensive approach, including
control of use in animal husbandry and horticulture, is needed,
but this is beyond the remit of this review [1]. Many questions
about AMS in humans remain. Uncertainty persists about the
deﬁnition, measurement and interpretation of outcomes.
Often, AMS programmes evaluate their success with surrogate
measures, such as overall antibiotic use density. The best way
to measure antibiotic use and what benchmarks to choose are,
however, far from clear [59]. Adjustment for differences in the
case mix of the patient populations seen by different institu-
tions or practitioners is another area of uncertainty [60].
Things become even murkier when we move from a quanti-
tative to a qualitative perspective and try to deﬁne ‘appropri-
ate’ and responsible antibiotic use (in the context of the
Innovative Medicines Initiative, a joint undertaking between the
European Union and the pharmaceutical industry association
EFPIA, the DRIVE-AB, project will try to address this issue
http://drive-ab.eu/ (accessed 16 October 2014)). The only
straightforward, universally agreed issue may be avoiding
antibiotics altogether when they are not needed. The recom-
mendation to avoid certain ‘high-risk’ antibiotics, such as
ﬂuoroquinolones and cephalosporins, is questioned by some
experts, as the long-term impact of replacing these antibiotics
with other agents is unclear [61]. Other cherished strategies,
such as de-escalation, individualized dosing, and reduced
duration of therapy, still have to prove their value in curbing
AMR. The role and value of rapid diagnostics and biomarkers
in stewardship also require further evaluation [62,63].
Antibiotic campaigns have traditionally been focused on
children, as they contribute a high percentage of antibiotic
prescriptions. Recent analyses from the USA and France
suggest, however, that older adults may also constitute a
worthwhile target [4,26]. The impact of public campaigns on
AMR is also far from evident, as illustrated by a recent
simulation study, illustrating the knowledge gaps regarding the
emergence and spread of resistance in individuals and popu-
lations [64].
The experience that we share here illustrates that there is
still much to be learned with regard to AMS. Our review
reveals that there remains a poor evidence base for the
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effectiveness of the myriad of AMS policies that have been
implemented across various countries. Even where policies
have demonstrated clear beneﬁt in reducing antimicrobial
misuse, a full evaluation of the successful policy has often been
lacking, with little available information on critical aspects such
as cost-effectiveness, and inadequate descriptions of the
technical and regulatory environment necessary for imple-
mentation and regulatory changes.
Unfortunately, we will not have time to wait for solid
scientiﬁc evidence for all aspects of AMS, as by then it may be
too late to avert or mitigate the escalation of the emerging
AMR crisis. In our opinion, the examples mentioned in this
review illustrate that it is crucial to understand this problem
in detail in each country and develop interventions tailored
for each setting (e.g. regarding how much public ignorance
contributes to antibiotic overuse). A common theme of
successful AMS interventions around the globe is that they
have been tailored to local conditions, incorporated the
advice of opinion leaders, provided a well-developed rationale
for change, and received strong support from governmental
agencies and/or professional societies of the concerned
country. Furthermore, regulatory interventions have been
crucial in changing antibiotic prescribing practices and
policies, as shown in diverse countries such as Australia,
South Korea, Scotland, and Chile. It is evident that changing
behaviour with regard to antibiotic prescribing has to be a
long-term goal. This should be supported not only by
improving knowledge through education, but also by a better
understanding of prescribing ‘etiquette’, human factors, and
systems of care delivery [65].
In the Scottish example, the ‘goal-oriented’ or ‘target-ori-
ented’ approach combined with explicit feedback of data and a
requirement for action has led to some sustained success over
a 6-year period. This approach is supported by emerging
evidence that audit and feedback of prescribing data can be
highly effective if it is provided by a supervisor or colleagues, is
repeated several times, is delivered both orally and in writing,
and is combined with a speciﬁc target and action plan [66]. The
long-term evaluation of sustainability should be a component
of any intervention to improve antibiotic use.
We need more high-quality randomized trials to improve
the evidence base, particularly in relation to factors that
provide sustained success (or a lack thereof) in a range of
diverse resource and healthcare settings, but sharing our
experiences with ‘real-life’ AMS practitioners and learning
from the failures and successes of others may be just as
important. The words of Winston Churchill may provide some
consolation for discouraged antibiotic stewards: ‘success is not
ﬁnal, failure is not fatal: it is the courage to continue that
counts’.
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